Bouchey Financial Group Ltd purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the second quarter, according to its most recent filing with the SEC. The firm purchased 3,062 shares of the company’s stock, valued at approximately $238,000.
Other hedge funds have also bought and sold shares of the company. Resources Investment Advisors LLC. grew its stake in Merck & Co., Inc. by 9.1% during the second quarter. Resources Investment Advisors LLC. now owns 35,473 shares of the company’s stock worth $2,759,000 after purchasing an additional 2,971 shares during the period. Davidson Capital Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 13.9% during the 2nd quarter. Davidson Capital Management Inc. now owns 15,982 shares of the company’s stock worth $1,243,000 after buying an additional 1,956 shares in the last quarter. Brandywine Oak Private Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 57.7% during the 2nd quarter. Brandywine Oak Private Wealth LLC now owns 29,581 shares of the company’s stock worth $2,300,000 after buying an additional 10,829 shares in the last quarter. Boussard & Gavaudan Investment Management LLP acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $18,961,000. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Merck & Co., Inc. by 7.2% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 286,224 shares of the company’s stock valued at $22,259,000 after acquiring an additional 19,305 shares in the last quarter. 71.83% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have commented on MRK shares. Morgan Stanley cut shares of Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $90.00 to $85.00 in a report on Tuesday, September 7th. Truist started coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They issued a “buy” rating and a $92.00 target price for the company. JPMorgan Chase & Co. cut their price target on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday, June 9th. Zacks Investment Research upgraded Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price objective for the company in a report on Tuesday, August 24th. Finally, Truist Securities assumed coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They set a “buy” rating and a $76.79 target price on the stock. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $91.09.
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Wednesday, July 28th. The company reported $1.31 earnings per share for the quarter, meeting the consensus estimate of $1.31. The business had revenue of $11.40 billion for the quarter, compared to analysts’ expectations of $11.21 billion. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. During the same period last year, the business earned $1.37 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.51 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, October 7th. Investors of record on Wednesday, September 15th will be issued a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.52%. The ex-dividend date is Tuesday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 43.77%.
Merck & Co., Inc. Profile
Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Further Reading: What can cause a stock to outperform?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.